$1.48
1.37% yesterday
NYSE, Dec 30, 10:01 pm CET
ISIN
US20454B1044
Symbol
CMPX
Sector
Industry

Compass Therapeutics Target price 2024 - Analyst rating & recommendation

Compass Therapeutics Classifications & Recommendation:

Buy
88%
Hold
13%

Compass Therapeutics Price Target

Target Price $11.00
Price $1.48
Potential
Number of Estimates 8
8 Analysts have issued a price target Compass Therapeutics 2025 . The average Compass Therapeutics target price is $11.00. This is higher than the current stock price. The highest price target is
$32.00 2,062.16%
register free of charge
, the lowest is .
A rating was issued by 8 analysts: 7 Analysts recommend Compass Therapeutics to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Compass Therapeutics stock has an average upside potential 2025 of . Most analysts recommend the Compass Therapeutics stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.00 0.90

7 Analysts have issued a sales forecast Compass Therapeutics 2024 . The average Compass Therapeutics sales estimate is

$900k
Unlock
. This is
5.88% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.0m 17.65%
Unlock
, the lowest is
$850k 0.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $0.0
2025
$6.2m 590.74%
Unlock
2026
$61.2m 884.15%
Unlock
2027
$180m 194.53%
Unlock
2028
$365m 102.42%
Unlock

2 Analysts have issued an Compass Therapeutics EBITDA forecast 2024. The average Compass Therapeutics EBITDA estimate is

$-53.8m
Unlock
. This is
0.39% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-52.0m 2.97%
Unlock
, the lowest is
$-55.6m 3.75%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-48.5m 21.94%
2024
$-53.8m 11.00%
Unlock
2025
$-55.2m 2.51%
Unlock
2026
$-45.8m 17.03%
Unlock
2027
$-10.5m 77.01%
Unlock
2028
$142m 1,446.35%
Unlock

EBITDA Margin

2025
-887.13% 85.16%
Unlock
2026
-74.79% 91.57%
Unlock
2027
-5.84% 92.19%
Unlock
2028
38.82% 764.73%
Unlock

8 Compass Therapeutics Analysts have issued a net profit forecast 2024. The average Compass Therapeutics net profit estimate is

$-48.2m
Unlock
. This is
2.77% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-44.0m 11.11%
Unlock
, the lowest is
$-55.0m 11.12%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-45.4m 10.81%
2024
$-48.2m 6.07%
Unlock
2025
$-54.7m 13.56%
Unlock
2026
$-56.6m 3.51%
Unlock
2027
$690k 101.22%
Unlock
2028
$108m 15,533.33%
Unlock

Net Margin

2025
-879.76% 83.56%
Unlock
2026
-92.53% 89.48%
Unlock
2027
0.39% 100.42%
Unlock
2028
29.57% 7,482.05%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.33 -0.35
10.81% 6.06%
P/E negative
EV/Sales 80.40

8 Analysts have issued a Compass Therapeutics forecast for earnings per share. The average Compass Therapeutics <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.35
Unlock
. This is
2.78% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.32 11.11%
Unlock
, the lowest is
$-0.40 11.11%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.33 10.81%
2024
$-0.35 6.06%
Unlock
2025
$-0.40 14.29%
Unlock
2026
$-0.41 2.50%
Unlock
2027
$0.01 102.44%
Unlock
2028
$0.78 7,700.00%
Unlock

P/E ratio

Current -4.11 15.95%
2024
-4.17 1.46%
Unlock
2025
-3.67 11.99%
Unlock
2026
-3.55 3.27%
Unlock
2027
289.11 8,243.94%
Unlock
2028
1.86 99.36%
Unlock

Based on analysts' sales estimates for 2024, the Compass Therapeutics stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

80.40
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
223.20
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 85.13
2024
80.40 5.56%
Unlock
2025
11.64 85.52%
Unlock
2026
1.18 89.84%
Unlock
2027
0.40 66.04%
Unlock
2028
0.20 50.60%
Unlock

P/S ratio

Current
2024
223.20 5.56%
Unlock
2025
32.31 85.52%
Unlock
2026
3.28 89.84%
Unlock
2027
1.11 66.05%
Unlock
2028
0.55 50.60%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today